Clinical trials: Bladder
PTCH1 or SMO Activated Solid and Hematologic Tumors
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT02002689)
- Testing
- LDE225
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Carcinoma in Situ, Transitional Cell Carcinoma
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin…
- Conditions
- Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT01310803
- Testing
- VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Bladder Carcinoma
Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy
This randomized phase II/III trial studies gabapentin in reducing the need for pain medication in patients with bladder cancer undergoing surgery to remove the bladder and nearby tissue and organs.
- Trial name
- NCT02355886
- Testing
- Gabapentin, Questionnaire Administration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Detrusor Overactivity, Overactive Bladder
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
- Trial name
- SHRINK (NCT01093534)
- Testing
- solifenacin
- Where
- 79 sites in United States, Austria and 18 more
- Volunteers
- 547 people
- Sponsor
- Astellas Pharma Inc
Bladder Cancer
Steps to Eliminate Postoperative Problems
Radical cystectomy with urinary diversion is associated with substantial perioperative morbidity, including deep venous thrombosis, prolonged ileus, and postoperative functional decline.
- Trial name
- STEPP (NCT02880176)
- Testing
- Financial Incentive to Increase Ambulation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pennsylvania
Bladder Cancer
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01469221
- Testing
- Apaziquone
- Where
- 29 sites in United States, Czechia and 2 more
- Volunteers
- 47 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Bladder Dysfunction, Multiple Sclerosis
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction
The aims of this prospective, randomized study are: To assess the effect of clean intermittent catheterization (CIC) To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when…
- Trial name
- NCT00913510
- Testing
- CIC using LoFric Primo, Anticholinergic medication
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Wellspect HealthCare
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Superficial Bladder Cancer
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC.
- Trial name
- NCT02773849
- Testing
- ADSTILADRIN
- Where
- 34 sites in United States
- Volunteers
- 157 people
- Sponsor
- Ferring Pharmaceuticals
Pelvic Organ Prolapse, Uterine Prolapse
Efficacy Study of Vaginal Mesh for Prolapse
The primary aim of this double-blind, randomized clinical trial (RCT) is to test the hypothesis that the addition of a standardized technique of interpositional synthetic polypropylene mesh placement improves the one-year outcome…
- Conditions
- Pelvic Organ Prolapse, Uterine Prolapse, Vaginal Prolapse, Cystocele
- Trial name
- VAMP (NCT00475540)
- Testing
- synthetic monofilament polypropylene mesh
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Medstar Health Research Institute
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Urinary Tract Infection, Vesicoureteral Reflux
Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.
- Trial name
- NCT02786810
- Testing
- Sulfur hexafluoride type-a lipid microspheres
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
Bladder Cancer
Study of Weekly Radiotherapy for Bladder Cancer
Background Localised muscle invasive bladder cancer (MIBC) is life-threatening and can cause significant symptoms. Around 50% of patients with MIBC who are referred for radiotherapy are unfit for standard radical treatment…
- Trial name
- HYBRID (NCT01810757)
- Testing
- Standard planning radiotherapy, Adaptive planning radiotherapy
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Catheter; Infection (Indwelling Catheter), Catheter Infection
Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal
Over the last decade, there has been great emphasis on reducing the incidence of hospital-acquired infections, including catheter-associated UTI (CAUTI).
- Conditions
- Catheter; Infection (Indwelling Catheter), Catheter Infection, Catheter-Related Infections, Catheter Bacteraemia
- Trial name
- NCT03447639
- Testing
- Povidone-iodine irrigation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Corewell Health East
Bladder Cancer
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer.
- Trial name
- NCT01489813
- Testing
- Genistein, Sugar pill
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Interstitial Cystitis, Painful Bladder Syndrome
Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Interstitial cystitis/Painful bladder syndrome (IC/PBS) is a chronic debilitating condition that severely impacts between 2.7 and 6.5 percent of women in the United States.
- Trial name
- NCT02517996
- Testing
- Lidocaine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
BK Virus Infection, Hemorrhagic Cystitis
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).
- Trial name
- NCT04390113
- Testing
- Posoleucel (ALVR105)
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 97 people
- Sponsor
- AlloVir